SOUTH SAN FRANCISCO, Calif. — September 16, 2026
Mission Bio announced the launch of Tapestri® Triomics, a new expansion of its Tapestri Platform designed to simultaneously analyze DNA, RNA and protein within the same cell. The capability connects genotype, gene expression and phenotype at single-cell resolution, allowing researchers to examine how genetic alterations influence cellular behavior without relying on measurements generated from separate platforms. Mission Bio introduced the technology during World Single-Cell Day, an inaugural virtual event focused on advances in single-cell technologies for disease biology, therapeutic development and cellular research. By bringing three molecular dimensions together in the same cell, Triomics extends the Tapestri Platform beyond its established single-cell DNA and multiomic capabilities and provides researchers with an integrated approach to investigating complex biological systems.
Triomics Connects Genotype With Cellular Function
Tapestri Triomics is designed to connect genetic changes with downstream cellular responses and phenotypes, creating a more comprehensive view of individual cells. DNA measurements can identify genetic alterations, RNA can reveal changes in gene expression, and protein measurements can provide information about resulting cellular characteristics. Mission Bio said analyzing these signals simultaneously can help researchers move beyond determining which cells carry a mutation toward understanding how those mutations affect cellular biology. Early work with the technology has demonstrated its application in hematologic disease, including research by Terra L. Lasho, Ph.D., of Mayo Clinic, and colleagues using bone marrow from patients with ASXL1-mutant myeloid disease. The researchers integrated genome, transcriptome and protein measurements to compare mutant and wild-type clones and investigate their potential contributions to disease progression.
Single-Cell Platform Supports Disease and Therapeutic Research
The Triomics launch expands the potential applications of the Tapestri Platform across disease biology and therapeutic development. Mission Bio’s single-cell technology is used to identify rare cell populations, investigate mechanisms associated with treatment resistance and response, and establish quality metrics for advanced medical therapies. The ability to measure genotype, transcriptome and protein in the same cell could provide researchers with additional context when studying clonal populations and disease progression. Such integrated analysis is particularly relevant to complex research areas including cancer, pharmaceutical development, and cell and gene therapy programs, where genetic changes may produce different cellular responses within the same broader population. Mission Bio said Triomics extends its existing single-cell multiomics foundation while reducing the need for researchers to combine measurements generated across separate analytical platforms. The technology is currently available for research use only.
Advertisement
Mission Bio Prepares Triomics Showcase at ASHG 2026
Mission Bio will further showcase Tapestri Triomics at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montréal, Canada. The technology will be featured at the company’s exhibition booth and in a presentation by Dr. Lasho titled “Single-Cell Multi-Omic Dissection of ASXL1-Mutant Clonal Hematopoiesis: Integrating Genotype, Transcriptome, and Protein in Myeloid Disease Progression.” The presentation is expected to highlight how integrated single-cell measurements can be applied to investigate the relationship between mutations and disease biology. The launch strengthens Mission Bio’s focus on single-cell multiomics as a research platform for complex biological questions, while extending Tapestri into simultaneous DNA, RNA and protein analysis. With Triomics now available for research use and an ASHG showcase planned, Mission Bio is expanding the Tapestri Platform toward more integrated single-cell analysis for disease research, drug development and advanced cell and gene therapy programs.
Source:Mission Bio,, press release
